Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by country, state, or city

Search by locations

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Japan”

Predicting BCG ResponseRecruiting
NCT04564781N/AUpdated Jul 6, 2026
Sponsor: Cedars-Sinai Medical Center
Bladder Cancer
United States, Australia, Japan
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal DiseaseActive Not Recruiting
NCT04020055Phase 3Updated Jul 6, 2026
Sponsor: Amicus Therapeutics
Fabry Disease
United States, Australia, Japan, Portugal, Spain +1 more
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)Active Not Recruiting
NCT05714202Phase 3Updated Jul 6, 2026
Sponsor: Janssen Research & Development, LLC
Bladder Cancer
United States, Argentina, Australia, Belgium, Brazil +16 more
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionActive Not Recruiting
NCT04273945Phase 3Updated Jul 6, 2026
Sponsor: Actelion
Pulmonary Arterial Hypertension
United States, Argentina, Australia, Austria, Belarus +37 more
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 YearsCompleted
NCT04899336Phase 3Updated Jul 6, 2026
Sponsor: Janssen Research & Development, LLC
Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
United States, Australia, Canada, China, Colombia +16 more
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisCompleted
NCT06624228Phase 3Updated Jul 6, 2026
Sponsor: UCB Biopharma SRL
Psoriatic Arthritis
United States, Australia, Bulgaria, Canada, Czechia +6 more
A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompleted
NCT04009499Phase 3Updated Jul 6, 2026
Sponsor: UCB Biopharma SRL
Psoriatic Arthritis
United States, Australia, Belgium, Canada, Czechia +9 more
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple MyelomaActive Not Recruiting
NCT04181827Phase 3Updated Jul 6, 2026
Sponsor: Janssen Research & Development, LLC
Multiple Myeloma
United States, Australia, Belgium, Denmark, France +11 more
A Study of Milvexian Versus Apixaban in Participants With Atrial FibrillationActive Not Recruiting
NCT05757869Phase 3Updated Jul 6, 2026
Sponsor: Janssen Research & Development, LLC
Atrial Fibrillation
United States, Argentina, Australia, Belgium, Brazil +34 more
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid TumorsRecruiting
NCT06535607Phase 2Updated Jul 6, 2026
Sponsor: AstraZeneca
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) · Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) · Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy) · Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
United States, Australia, Brazil, Canada, China +7 more
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour ResectionActive Not Recruiting
NCT05120349Phase 3Updated Jul 6, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Argentina, Brazil, Canada, China +15 more
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruiting
NCT05552222Phase 3Updated Jul 6, 2026
Sponsor: Janssen Research & Development, LLC
Multiple Myeloma
United States, Australia, Austria, Belgium, Brazil +20 more
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's DiseaseRecruiting
NCT06233461Phase 2Updated Jul 6, 2026
Sponsor: Takeda
Crohn's Disease
United States, Australia, Belgium, Brazil, Bulgaria +20 more
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary AldosteronismRecruiting
NCT07007793Phase 3Updated Jul 6, 2026
Sponsor: AstraZeneca
Primary Hyperaldosteronism
United States, Australia, Canada, China, France +7 more
A Long-term Study for Participants Previously Treated With Ciltacabtagene AutoleucelRecruiting
NCT05201781Phase 4Updated Jul 6, 2026
Sponsor: Janssen Research & Development, LLC
Multiple Myeloma
United States, Belgium, China, France, Israel +3 more
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisRecruiting
NCT05652335Phase 1Updated Jul 6, 2026
Sponsor: Janssen Research & Development, LLC
Relapsed or Refractory Multiple Myeloma · Previously Treated Amyloid Light-chain (AL) Amyloidosis
United States, Belgium, France, Japan, Netherlands +2 more
Asciminib Roll-over StudyRecruiting
NCT04877522Phase 4Updated Jul 6, 2026
Sponsor: Novartis Pharmaceuticals
Chronic Myelogenous Leukemia · Leukemia, Myelogenous, Chronic, BCR-ABL Positive
United States, Argentina, Austria, Brazil, Bulgaria +24 more
A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate CancerActive Not Recruiting
NCT04898634Phase 1Updated Jul 6, 2026
Sponsor: Janssen Research & Development, LLC
Prostatic Neoplasms
United States, China, France, Japan, Netherlands +1 more
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis PigmentosaActive Not Recruiting
NCT05926583Phase 3Updated Jul 6, 2026
Sponsor: Janssen Pharmaceutical K.K.
Retinitis Pigmentosa
Japan
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial TherapyActive Not Recruiting
NCT04923893Phase 3Updated Jul 6, 2026
Sponsor: Janssen Research & Development, LLC
Multiple Myeloma
United States, Argentina, Australia, Austria, Belgium +21 more
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder CancerActive Not Recruiting
NCT05567185Phase 1Updated Jul 6, 2026
Sponsor: Janssen Pharmaceutical K.K.
Urinary Bladder Neoplasms · Receptors, Fibroblast Growth Factor
Japan
Phase 3 Study of KP-100LI in Subjects With Vocal Fold ScarActive Not Recruiting
NCT05627648Phase 3Updated Jul 6, 2026
Sponsor: Kringle Pharma, Inc.
Vocal Fold Scar
Japan
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck CancerRecruiting
NCT06385080Phase 1, Phase 2Updated Jul 6, 2026
Sponsor: Janssen Research & Development, LLC
Squamous Cell Carcinoma of Head and Neck
United States, China, France, Germany, Japan +6 more
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruiting
NCT07227415Phase 1, Phase 2Updated Jul 6, 2026
Sponsor: Pfizer
Carcinoma, Renal Cell · Advanced Renal Cell Carcinoma · Renal Cancer · Renal Neoplasm
United States, Australia, China, Germany, Japan +1 more
Multisite Inventory of Neonatal-Perinatal Interventions (MINI) Minimum DatasetRecruiting
NCT05685745N/AUpdated Jul 6, 2026
Sponsor: The University of Texas Health Science Center, Houston
Infant, Extremely Premature · Obstetric Labor, Premature · Premature Birth · Intensive Care, Neonatal
United States, Australia, Canada, Czechia, Germany +3 more

Previous page Next page